Metabolic & Endocrine
Glycogen Storage Disease Due to Glucose-6-Phosphatase Deficiency Type IA
2
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Glycogen Storage Disease Due to Glucose-6-Phosphatase Deficiency Type IA is an early-stage landscape with 2 programs across 2 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Boehringer Ingelheim. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)